Purified lam

Antigens derived from M. tuberculosis, HIV, and various control pathogens were utilized across multiple assays. An HIV-1 clade B/C consensus gp120 antigen was acquired from Immune Technology. PPD was received from the Statens Serum Institute. Purified LAM, ESAT6, CFP10, Ag85A, and Ag85B were all acquired from BEI Resources. Tetanus toxoid was received from Massachusetts Biologics. PPSV23 is the pneumococcal 23-valent vaccine from Merck Sharp & Dohme Corporation. A pool of recombinant influenza hemagglutinin (HA) antigens (HA1-B/Florida/4/2006, HA-B/Malaysia/2506/2004, H1N1-A/Solomon island/3/2006, H3N2-A/Wisconsin/67/X-161/2005, H3N2-A/Brisbane/10/2007, H1N1-A/New Caledonia/20/99, and H1N1-A/Brisbane/59/2007; Immune Technologies) representing dominant strains from the past 10 years were combined to generate the influenza HA control antigen.

Two hundred and seven Mtb antigens, selected based on their discriminatory potential for TB diagnosis and their immunogenicity (Franken et al., 2000 (link); Serra-Vidal et al., 2014 (link); Coppola and Ottenhoff, 2018 (link)) were obtained from Dr. Tom Ottenhoff and Kees Franken (Nziza et al., 2022 (link)), and prepared as previously described (Franken et al., 2000 (link); Commandeur et al., 2013 (link)). Purified LAM was obtained from BEI Resources and purified protein derivative (PPD) was received from the Statens Serum Institute. Influenza Virus A, pertussis and gp120 were purchased from ImmuneTech.